These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30730659)

  • 1. Adalimumab (Humira°) and hidradenitis suppurativa.
    Prescrire Int; 2017 Apr; 26(181):94-96. PubMed ID: 30730659
    [No Abstract]   [Full Text] [Related]  

  • 2. Adalimumab (Humira
    Gupta AK; Cernea M; Abramovits W; Vincent KD
    Skinmed; 2016; 14(4):291-294. PubMed ID: 27784520
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
    N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
    Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
    JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants.
    Zubkov MR; Waldman RA; Wu R; Grant-Kels JM
    Cutis; 2021 Oct; 108(4):199-200. PubMed ID: 34846999
    [No Abstract]   [Full Text] [Related]  

  • 7. Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction.
    Company-Quiroga J; Alique-García S; Martínez-Morán C; Khedaoui R; Romero-Maté A; Borbujo J
    Indian J Dermatol Venereol Leprol; 2019; 85(4):422-425. PubMed ID: 31115357
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of patients with hidradenitis suppurativa.
    Martorell A; Caballero A; González Lama Y; Jiménez-Gallo D; Lázaro Serrano M; Miranda J; Pascual JC; Salgado-Boquete L; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():32-42. PubMed ID: 28081768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Squamous cell carcinoma of the cervix arising in a patient on adalimumab � a need for cervical screenings in patients on tumor necrosis factor inhibitors.
    Bessaleli E; Scheinfeld N; Kroumpouzos- G
    Dermatol Online J; 2018 May; 24(5):. PubMed ID: 30142745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series.
    Yen CF; Huang YH; Chi CC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):223-226. PubMed ID: 31389375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.
    Gupta AK; Studholme C
    Skin Therapy Lett; 2016 Jul; 21(4):1-4. PubMed ID: 27388530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
    Cline A; Pichardo RO
    Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.
    Diamantova D; Lomickova I; Cetkovska P
    Acta Dermatovenerol Croat; 2014; 22(4):291-3. PubMed ID: 25580790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic.
    Benesh G; Andriano TM; Babbush KM; Hosgood HD; Cohen SR
    J Cutan Med Surg; 2021; 25(4):446-448. PubMed ID: 33625899
    [No Abstract]   [Full Text] [Related]  

  • 16. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
    Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
    Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
    [No Abstract]   [Full Text] [Related]  

  • 18. Adalimumab-Induced Neutropenia in a Man With Hidradenitis Suppurativa.
    Rueda Carnero JM; Nieto Rodríguez D; de Lucas Laguna R; Feito Rodríguez M
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):273-274. PubMed ID: 31980127
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.
    Canal Garcia E; Vargas Ramos JDP; Aguayo Ortiz R
    Australas J Dermatol; 2020 Nov; 61(4):e448-e449. PubMed ID: 32567672
    [No Abstract]   [Full Text] [Related]  

  • 20. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
    AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.